18.14
-6.36(-25.96%)
Currency In USD
| Previous Close | 24.5 |
| Open | 24.66 |
| Day High | 24.76 |
| Day Low | 15.7 |
| 52-Week High | 50.4 |
| 52-Week Low | 15.7 |
| Volume | 6.36M |
| Average Volume | 1.01M |
| Market Cap | 506.3M |
| PE | -8.81 |
| EPS | -2.06 |
| Moving Average 50 Days | 31.92 |
| Moving Average 200 Days | 31.22 |
| Change | -6.36 |
If you invested $1000 in LENZ Therapeutics, Inc. (LENZ) since IPO date, it would be worth $1,119.75 as of December 14, 2025 at a share price of $18.14. Whereas If you bought $1000 worth of LENZ Therapeutics, Inc. (LENZ) shares 6 months ago, it would be worth $629.42 as of December 14, 2025 at a share price of $18.14.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
LENZ Therapeutics Announces MFDS Submission of New Drug Application for LNZ100 (VIZZ™) in South Korea for the Treatment of Presbyopia
GlobeNewswire Inc.
Dec 01, 2025 1:30 PM GMT
Submission of NDA in South Korea by Lotus Pharmaceutical results in the second ex-U.S. regulatory submission for VIZZSAN DIEGO and TAIPEI, Taiwan, Dec. 01, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co.
LENZ Therapeutics to Report Third Quarter 2025 Financial Results and Recent Corporate Highlights on November 5, 2025
GlobeNewswire Inc.
Oct 29, 2025 12:00 PM GMT
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-ap
LENZ Therapeutics Announces Commercial Product Availability of VIZZ™ in the United States
GlobeNewswire Inc.
Sep 30, 2025 12:00 PM GMT
VIZZ sample distribution initiated nationwide to Eye Care Professionals Commercial product shipments to be initiated in October to consumers with broad product availability by mid-Q4 2025 VIZZ is the first and only aceclidine-based eye drop approved